AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2010
Dec 13, 2010
33390_dirs_2010-12-13_e9eb65c1-8590-46d7-be60-d4caee1bbd06.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2010-12-09
Reporting Person: Polymeropoulos Mihael Hristos (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2010-12-09 | Common Stock | S | 17400 | $8.1092 | Disposed | 462600 | Direct |
| 2010-12-10 | Common Stock | S | 82600 | $8.1014 | Disposed | 380000 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.15, inclusive.